Many of you seem to feel the Valeant bid is inadequate but the stock was trading in the $130s at the time and you were not bidding it up to $180. Maybe we shareholders did not know the secret value of AGN but surely we do now, yet the stock drops daily from the inadequate offer from Valeant to an even lower price. Hmmm...If you all think it is worth $200 a share then you should be buying this grand bargain.
Now you may love Mr. Pyott but he needs to earn a return for all shareholders even the recent ones and the ones he may not actually like; if someone else thinks they can do better, they need to pay up and they get their right to choose. You may like Mr. Pyott, trust me he will make lots of money either way, and land at a new company where maybe you can take the ride all over again. Who knows maybe Valeant will make him the CEO! BTW the dividend is an insulting low for all the non-GAAP profit AGN reports.
I was first introduced to Thoratec in early 2009 and was impressed. the stock was around $33. Imagine my surprise when an ex-director mentioned it today at lunch and the stock was still at $33! Did I slip into a time warp? I wondered how such a great technology could produce not shareholder returns in over 5 years, I had to look to see if the same CEO was at the helm. Yep it sure looks like it. Sometimes you really have to wonder what it takes to get a board off of its dead duff and do something.
Marcy l'Etoile, France - April 23, 2014
FIRST-QUARTER 2014 BUSINESS REVIEW FIOR BIOMERIEUX
• Up 7.9%, including BioFire and at constant exchange rates
• Up 4.1% like-for-like*, in line with the target for the year
o Continued stabilization in Western Europe, up 1.4%*
o Sustained solid growth in North America, up 5.4%*
• Up 3.3%, on a reported basis
2014 objective of 3 - 5% organic sales growth maintained
Integration of BioFire effectively underway
Alexandre Mérieux, Chief Executive Officer, said: “During the first quarter of 2014, bioMérieux's sales rose by 4.1% at constant exchange rates and scope of consolidation, in line with our target for the year, and by 7.9% after consolidating the sales from BioFire, acquired in mid-January 2014. Sales continued to trend upwards in Europe and North America. BioFire’s FilmArray® system pursued its rapid expansion, with 55 new instruments installed since the company’s acquisition. In addition, we continued to roll out VIDAS® 3, whose application for approval was filed with Chinese authorities, and we prepared for the forthcoming market launch of our innovative new clinical microbiology platforms. Lastly, in line with our strategic plan, we are deploying a new operating organization designed to effectively meet public health challenges and our customers' needs around the world”.
It looks like the Douglas Ingram, president sold 98.8% of his holdings (84,000 shares) on Feb 14th and David Pyott, CEO sold 60% of his shares (252,000 shares) two days earlier. Hardly makes me feel good about holding my shares.
If your take is the money is dead, you should sell and put the cash in a savings account at wells fargo. I hear them are paying 2-3 % below the inflation rate. It is pretty hard to grow sales at a 100% clip and get new accounts trained properly. That said, they need to work on the gross margin, revenue is not much good if there is no margin to cover overhead.
UPDATE 1-FDA OKs Merck OTC version of overactive bladder drug
Fri Jan 25, 2013 12:40pm EST
Jan 25 (Reuters) - U.S. health regulators approved Merck & Co's nonprescription version of Oxytrol to treat overactive bladder in women ages 18 and older, the agency said on Friday.
The U.S. Food and Drug Administration said the over-the-counter version of Oxytrol would be available for women only and that the drug remained available to men by prescription.
Overactive bladder, which affects an estimated 33 million Americans, is a condition in which the bladder squeezes too often or without warning. Symptoms include leaking urine, feeling a sudden and urgent need to urinate, and frequent urination.
Oxytrol for Women is a patch that contains oxybutynin, a medicine that helps relax the bladder muscle, and is designed to be applied to the skin every four days, the FDA said.
Oxybutynin belongs to a class of drugs known as anticholinergics. Pfizer Inc's Detrol is the market leader in the class with annual sales of about $700 million.
Oxytrol will be the first drug in the class to be sold over the counter. Merck licensed exclusive rights to sell OTC Oxytrol from Actavis Inc, the generic drugmaker formerly known as Watson Pharmaceuticals.
Merck said it expected the OTC patch to be available in the fall.
The FDA decided to approve the OTC version of the Merck drug, based on the results of nine studies of women that demonstrated that consumers can understand the information on the label, properly determine whether the product is right for them, and use the drug appropriately, the agency said.
Last week, the FDA approved the popular wrinkle treatment Botox from Allergan Inc to treat overactive bladder in people who cannot tolerate drugs from the class to which Oxytrol belongs or are not helped by these medications.
Allergan's BOTOX® (onabotulinumtoxinA) Receives U.S. Food and Drug Administration Approval for the Treatment of Overactive Bladder for Adults Who Have an Inadequate Response to or Are Intolerant of an Anticholinergic Medication.
I am pleased to see management has a new corporate logo but it looks like Allergan has been working on taking the market.
The CEO of Sientra, Hani Zeini, is giving a presentation this wednesday in Santa Barbara. Since all the breast implant manufacturers are in SB it should be interesting.
I sold out my shares at $42 figuring lawsuit would torpedo deal. I did okay but hate to see so much money left on table because of lawyers.
Medicis (MRX) is falling after the company disclosed in an SEC filing that it had been sued by dermatological product maker Q-Med. The lawsuit alleges that Q-Med has the right to block Medicis' pending merger with Valenant Pharmaceuticals (VRX). Q-Med, whose dermal filler products are sold by Medicis, is asking a court to affirm that it has the right to block the merger, as well as a preliminary injunction that would prohibit Medicis from transferring to Valeant its right to distribute Q-Med products.
This team is a chronic under performer. I sold ZMH and bought SYK and its been a #$%$ trade off ever since. They need to get the business into the hands of a competent management team.
David Pyott sold 616,300 shares on October 4-5. It appears he still owns 399,151 directly, through his trust, 401K and ESOP. This looks to be well over 60% of his holdings. Mr. Pyott joined Allergan in January 1998 as President and Chief Executive Officer and now serves as Chairman of the Board (since 2001), President and CEO.
• Total sales are up 13% about $20 million but UGG sales are down for quarter.
• From the press release “UGG® brand sales decreased 0.3% to $107.9 million compared to $108.3 million for the same period last year.
• Teva® brand sales decreased 15.4% to $34.1 million compared to $40.3 million for the same period last year.”
• All the growth came from acquisition of Sanuk brand ($28 million) and core business is down year on year.
• Operating losses ballooned uncontrolled to $28.5 million from 10.8 million loss last year.$174 million in sales and the company has a loss? Now that is spending.
• Sadly, management is very busy working on their new corporate headquarters while the business flounders.
To be accurate the insider did not buy shares. Someone in his family did. So do not take too much credit here. These guys are selling out like crazy.
stop selling the shares every time the window opens. Its hard for longs to make a case for ownership when the management won't.
Sorry I did not sell last year.
Allergan is a strong DTC marketer. They will expand the market via advertising and awareness. With Latisse (for lashes) they were able to bundle the product promotionally with Juvederm and Botox for cosmetic use. They basically gave the prodct away to drive adoption and use. I do not think those tools will be available to market to urologists given reimbursement constraints. (They were fined $600 million last year.) Just the same, expect the market to expand and they will take a large share. Hopefully UPI can hang on to some share but it best get serious about have a tough competitor.
Boy am I happy I found this stock. I had been shredding my cash using a 20 sheet shredder and this is so much faster! This management team is great! Copying patented technologies and trademarks is a sign of world class performance. Boy am I relieved the court validated NuVasive’s technology and gave Medtronic a $100 million to drive home the point. Its great to hear that the loss of $100 million has in “no way impact the daily operations of our business.” Not until tomorrow anyway. I think we need another round of bonuses. Comp committee, another round please.
I am not a shareholder of Netflix but sadly I am a customer. I would jump at a chance to change to any other service. This may be the worst run company on the planet. I have no idea what is going on with steaming and dvd service. The year over year profits were up some 56% per Yahoo finance. I suppose they thought that was too much so they decided to torture the customers into quitting the service. Good luck .. you will need it with this management team.